It is a life sciences public limited company based in Bengaluru, Karnataka, India, established in 2021.
2021 | Bengaluru, Karnataka, India | AmalgamatedBiofusion Therapeutics Limited, a amalgamated public limited company, was established on 18 March 2021 in Bengaluru, Karnataka, India. Engaging in biotechnology within the manufacturing sector, it holds CIN: U73100KA2021PLC145487. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹1.50 M and a paid-up capital of ₹0.50 M.
Employing 3 professional, Its leadership includes Kiran Mazumdar Shaw (Director), Siddharth Mittal (Director), Karaikal Narayanaswamy Murali Krishnan (Director). Past directors included John Mccallum Marshall Shaw, Karaikal Narayanaswamy Murali Krishnan. It holds no open charges and ₹42.71 Cr settled loans. Its latest AGM occurred on 11 August 2023, with the balance sheet filed on 31 March 2023. It is based at 4Th Floor, Pod2, Brc Building, Biocon Special Economic Zone, Bommasandra Industrial Ar, Ea, Bengaluru, Karnataka, 560099.
U73100KA2021PLC145487
145487
18 March 2021
₹1.50 M
₹0.50 M
Roc Bangalore
Unlisted
Amalgamated
Explore comprehensive insights into Biofusion Therapeutics Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kiran Mazumdar Shaw | Director | 18 Mar 2021 | Current |
| Siddharth Mittal | Director | 18 Mar 2021 | Current |
| Karaikal Narayanaswamy Murali Krishnan | Director | 27 Jul 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 31 Jul 2022 | Past |
| Pramod Abcsdd | Additional Director | 10 Aug 2023 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Biofusion Therapeutics Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.67% increase. The company also saw a substantial improvement in profitability, with a 2670.46% increase in profit. The company's net worth Soared by an impressive increase of 2642.46%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Biofusion Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹427,141,825.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Apr 2022 | Citi Bank N.A. | ₹42.71 Cr | Satisfied |
Explore comprehensive loan charge details -
Biofusion Therapeutics has a workforce of 3 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Biofusion Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biofusion Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Biofusion Therapeutics Limited last Annual general meeting of members was held on 11 Aug 2023 as per latest MCA records. was documented.
Progress on Biofusion Therapeutics Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Bangalore. was documented.
The activity A charge registered on 21 Apr 2022 via Charge ID 100581935 with Citi Bank N.A. was fully satisfied on 26 Dec 2022. was completed.
Progress on Karaikal Narayanaswamy Murali Krishnan was appointed as a Director was appointed as a Director on 27 Jul 2022 & has been associated with this company since 3 years 4 months . was documented.
Progress on A charge with Citi Bank N.A. amounted to Rs. 427.14 M with Charge ID 100581935 was registered on 21 Apr 2022. was documented.
The activity Kiran Mazumdar Shaw was appointed as a Director was appointed as a Director on 18 Mar 2021 & has been associated with this company since 4 years 8 months . was completed.
The CIN of Biofusion Therapeutics Limited is U73100KA2021PLC145487.
Biofusion Therapeutics Limited is headquartered at 4Th Floor, Pod2, Brc Building, Biocon Special Economic Zone, Bommasandra Industrial Ar, Ea, Bengaluru, Karnataka, 560099.
Biofusion Therapeutics Limited was incorporated on 18 March 2021.
The current directors of Biofusion Therapeutics Limited are
The primary industry of Biofusion Therapeutics Limited is Manufacturing.
Biofusion Therapeutics Limited is unlisted.
The authorized capital of Biofusion Therapeutics Limited is ₹1.50 M, and the paid-up capital is ₹0.50 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX